UNIMED, a distinguished name in pharmaceuticals and medical equipment distribution within the UAE and a division of the esteemed Mohamed & Obaid AlMulla Group, has recently solidified a strategic partnership with ADCAN Pharma, a prominent pharmaceutical company based in the UAE.
This alliance signifies a pivotal move towards advancing the UAE’s pharmaceutical industry, aligning with UNIMED’s core objectives of fostering self-sufficiency and driving down manufacturing costs, ultimately benefiting consumers across the nation.
The formal agreement was inked by Sherif Beshara, Group CEO of Mohamed & Obaid Almulla Group, and Mr. Zuhdi Sawalhi, CEO of ADCAN Pharma, highlighting the mutual commitment to innovation and collaborative progress within the sector.
In another notable development, UNIMED proudly announces its participation in DUPHAT 2024, the prestigious event renowned for showcasing cutting-edge trends and achievements in the pharmaceutical landscape. With its 29th edition set to unfold in Dubai, DUPHAT 2024 stands as a dynamic platform fostering knowledge exchange and networking among industry experts.
UNIMED’s involvement in DUPHAT 2024 underscores its dedication to staying at the forefront of industry advancements, contributing significantly to the evolution of healthcare solutions. The partnership with ADCAN Pharma further bolsters UNIMED’s mission to expand healthcare horizons, delivering enhanced value to its clientele and stakeholders.
